|
Genitope is a drug development company in arrested development. It had hoped to find new ways to fight cancer with old weapons, but now it is just hoping to find a future. The company was researching immunotherapy treatments for cancer, using the body's own immune system to fight tumors. Genitope's leading drug candidate, MyVax, was a patient-specific immunotherapy that would specify the genetic makeup of the tumor, activate the patient's immune system to attack it, and cause no damage to cells other than the tumor. However, the drug did not do well in early clinical trials, and when the FDA requested additional trials for further review, Genitope chose to scrap the whole program.
|
| | | Contact Information | |
Address: |
6900 Dumbarton Circle
Fremont, CA 94555-3651
| | Phone: | 510-284-3000 | | Fax: | 512-284-3100 |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
Chairman, CEO, Interim CFO, and Principal Financial Officer:
Dan W. Denney Jr.
| | • |
VP Information Technology:
H. David Miller
|
|
|
